CytomX’s Probody T-Cell Platform Produces Astellas Pact
Bispecifics collaboration with Astellas May Be Worth $1.6bn For CytomX
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
